Rare case of ocular tuberculous
noduloulcerative scleritis
Pentapati M1, Shah S2,
Suresh Babu G3
1Dr Pentapati Mridula, MS Ophthalmology, Senior Resident, Department of
Ophthalmology, Bangalore Medical College & Research
Institute, Bangalore, India, 2Dr Suchi Shah, MS
Ophthalmology, Ex-Senior Resident, Department of Ophthalmology,
Bangalore Medical College & Research Institute, Bangalore,
India, 3Dr Gangasagara Suresh Babu, Associate Professor of
Ophthalmology, Bangalore Medical College & Research Institute,
Bangalore, India
Address for
Correspondence: Dr. Suchi Shah, MS Ophthalmology,
Ex-Senior Resident, Department of Ophthalmology, Bangalore Medical
College & Research Institute, Bangalore – India,
suchi.shah.87@gmail.com
Abstract
Tuberculosis is an endemic disease in developing countries like India.
A scleral tuberculoma is a very rare manifestation of this disease.
Ocular involvement is usually secondary to pulmonary tuberculosis or in
cases of disseminated tuberculosis. A very high index of suspicion is
necessary in endemic areas as the condition can be sight threatening.
We hereby report a rare case of ocular tuberculosis presenting as a
noduloulcerative lesion of the sclera. An otherwise healthy, 26 year
old female patient, presented with redness, pain and watering in the
right eye since two months. On examination an oval noduloulcerative
scleral lesion was noted associated with cells and flare in the
anterior chamber. Patient had a normal vision and posterior segment.
After ruling out all other causes of ocular inflammation and with a
positive Mantoux test, the patient was started on oral antituberculous
treatment. The lesion faded and resolved over a period of two weeks.
This case emphasises the necessity of ruling out tuberculosis in
endemic areas where the clinical manifestations of the disease can be
obscure. Early diagnosis and prompt systemic treatment gives a
favourable prognosis.
Keywords:
Ocular Tuberculosis, Tuberculous Scleritis, Nodular Scleritis,
Noduloulcerative Scleritis
Manuscript received:
7th May 2015, Reviewed: 15th
May 2015
Author Corrected:
24th May 2015, Accepted
for Publication: 6th June 2015
Introduction
Tuberculosis has been declared by the World Health Organization as a
global emergency since it remains the single most common cause of
morbidity and mortality worldwide. It causes nearly three million
deaths each year [1]. Tuberculosis is a clinical disease caused by
infection with Mycobacterium tuberculosis and is characterized
pathologically by the formation of granulomas [2]. Presence of a
tuberculoma in the sclera is a very rare presentation of ocular
tuberculosis [3]. Further, ocular tuberculosis is a common cause of
infectious uveitis in endemic countries like India [4]. Nearly every
ocular tissue can be affected by tuberculosis giving rise to a wide
variety of clinical manifestations which include phlyctenular
conjunctivitis, scleritis, uveitis, retinal vasculitis, multifocal
serpiginoid choroiditis, choroid tubercles, subretinal abscess, and
optic neuritis [5]. Ocular mycobacterial tuberculosis infection is most
often a result of haematogenous spread during pulmonary or
extrapulmonary tuberculosis. We hereby report a rare case of ocular
tuberculosis presenting as noduloulcerative scleritis.
Case
Discussion
A 26 year old female patient presented to the ophthalmology out patient
department with complaints of redness, pain and watering in the right
eye since two months. Patient had no history of trauma, diminished
vision, photophobia, discharge or any systemic complaints. Visual
acuity in both eyes was 20/20 for distance and N6 for near.
Slit lamp examination of the right eye revealed a 3 x 2 mm obliquely
oval noduloulcerative lesion of the sclera at one o’clock
position close to the limbus. Deep congestion was noted around the
lesion. (Fig. 1)
Fig 1: Slit lamp image of
right eye shows an obliquely Fig 2: Slit
lamp image shows a flattened scleral nodule
oval noduloulcerative
scleral lesion with
surrounding
reduced congestion
Congestion
close to the limbus
Cornea was clear, anterior chamber examination revealed 1+ cells and 1+
flare. Pupil was round, regular and reacting to light. Rest of the
anterior segment examination was within normal limits. On instilling
ten percent phenylephrine eye drops, congestion persisted at the
nodule. Dilated fundus examination was carried out with indirect
ophthalmoscope using a 20D lens and was found to be within normal
limits. Anterior and posterior segment examinations of left eye were
within normal limits.
Haematological investigations were done which included a complete blood
count, erythrocyte sedimentation rate (ESR), fasting and post prandial
blood sugars, rheumatoid factor, anti nuclear antibody (ANA) profile,
VDRL, enzyme-linked immunosorbent assay (ELISA) for HIV. ESR was raised
to 40mm per hour with the remaining investigations being within normal
limits.
Mantoux test was done by injecting 0.1 ml (five Tuberculin Units) of
purified protein derivative of Mycobacterium Tuberculosis bacilli
intradermally on the ventral aspect of left forearm. Reading taken
after 72 hours revealed a circular induration of 15mm in its widest
diameter. Roentogram of chest with a postero-anterior view was normal.
A complete physical examination was done by a physician whereby no
abnormalities were detected.
Based on the above clinical findings and investigations, after ruling
out other identifiable causes of ocular inflammation, with tuberculosis
being endemic in our current setting, we provisionally diagnosed the
patient as having right eye tuberculous noduloulcerative scleritis.
A physician reference was made in view of starting anti-tuberculous
treatment. A four drug treatment regimen under category one was given
as per RNTCP (Revised National Tuberculosis Control Programme) [6].
Ethambutol (1200mg), Isoniazid (600 mg), Rifampicin (450 mg) and
Pyrazinamide (1500 mg) were used and patient was treated under Directly
Observed Therapy Shortcourse (DOTS) strategy [7,8].
Topically, patient was put on 2% hydroxyl propyl methyl cellulose
(HPMC) four times a day and 2% homatropine eye drops twice daily.
Topical steroids were avoided since it has been found that tuberculous
scleritis responds to systemic antituberculous treatment rather than
topical steroids [9].
Patient was reviewed every five days. At the end of first week, scleral
nodule flattened, congestion reduced and anterior chamber was quiet.
(Fig. 2)
The nodule and congestion disappeared completely by the end of one
month leaving a corresponding area of scleral thinning. (Fig. 3)
Fig.3- Slit lamp image
shows complete disappearance of nodule and congestion. Arrows show the
corresponding area of scleral thinning
Discussion
Keino et al. in a review of 83 patients with scleritis found that
diffuse scleritis is the most common presenting form of scleritis
(69%), while nodular scleritis is less common (11%). Of these, 55.5% of
patients with nodular scleritis were found to be Mantoux positive [10].
Biswas and Badrinath examined 2,010 eyes of patients with pulmonary
tuberculosis and found a 1.39% ocular involvement [11]. Sahu et al. in
a case series of 55 patients with ocular tuberculosis reported scleral
involvement in 14.5% cases [12]. However, the diagnosis of ocular
tuberculosis is often delayed since it is difficult to differentiate
its clinical manifestations from other infectious and non-infectious
inflammatory conditions.
It has been shown previously that empiric antituberculosis therapy in
the absence of bacteriological or histological proof of tuberculosis is
beneficial in suspected cases [13]. Further, resolution of the lesion
with commencing of antitubercular therapy pointed towards a causal
association of the lesion with Mycobacterium tuberculosis. For the same
reason histopathological analysis which is an invasive procedure was
not considered in the setting of an active inflammation.
In a retrospective case series of 26 eyes with mycobacterial ocular
inflammatory disease 38.5% of the cases had permanent loss of vision
secondary to delay in diagnosis. Of these, two cases were enucleated
after spontaneous perforation from uncontrolled necrotizing nodular
scleritis. A delay in the initiation of specific antitubercular therapy
can lead to recurrent or chronic inflammation and thereby long-standing
visual impairment in the affected eyes [14]. Tuberculous scleritis, in
absence of prompt treatment, is known to have a grave and dismal
prognosis leading to extensive scleral necrosis along with uveal
inflammation which can ultimately result in an unsalvageable eye [15].
Conclusion
Ocular tuberculous noduloulcerative scleritis, though rare, is still
prevalent in developing countries which are endemic for the disease. In
such settings, a high index of suspicion is crucial for diagnosis of
the condition. Early diagnosis and prompt treatment plays a key role
for this sight threatening condition, which if treated early gives a
favourable prognosis.
Funding:
Nil, Conflict of
interest: None initiated.
Permission
from IRB:
Yes
References
1. Centers for Disease Control and Prevention: Trends in tuberculosis
in United States. MMWR Morb Mortal Wkly Rep 2005;54(10):245-9.
2. Centers for Disease Control and Prevention: Case definitions for
infectious conditions under public health surveillance. MMWR Morb
Mortal Wkly Rep 1997;46(RR-10):1-55.
3. Biswas J, Madhavan HN, Gopal L, Badrinath SS. Intraocular
tuberculosis. Clinicopathologic study of five cases. Retina
1995;15(6):461-8. [PubMed]
4. Singh R, Gupta V, Gupta A. Pattern of uveitis in a
referral eye clinic in north India. Indian J Ophthalmol
2004;52(2):121–5. [PubMed]
5. Gupta V, Gupta A, Rao NA. Intraocular tuberculosis-an
update. Surv Ophthalmol 2007;52(6):561–87. [PubMed]
6. Khatri GR. The Revised National Tuberculosis Control Programme: a
status report on first 1,00,000 patients. Indian J Tuberc
1999;46:157–66.
7. Stop TB at the source. Geneva: World Health Organization;
1995. Report on the tuberculosis epidemic.
8. Geneva: World Health Organization; 2006. WHO: The stop TB
strategy, Building on and enhancing DOTS to meet the TB related
millennium development goals.
9. Sharma A, Thapa B, Lavaju P. Ocular tuberculosis: An
update. Nepal J Ophthalmol 2011;3(5):52-67. [PubMed]
10. Keino H, Watanabe T, Taki W, Nakashima C, Okada AA.
Clinical features and visual outcomes of Japanese patients with
scleritis. Br J Ophthalmol 2010;94(11):1459-63. [PubMed]
11. Biswas J, Badrinath S. Ocular morbidity in patients with
active systemic tuberculosis. Int Ophthalmol
1996;19(5):293–8. [PubMed]
12. Sahu GN, Mishra N, Bhutia RC, Mohanty AB. Manifestations
in ocular tuberculosis. Ind J Tub 1998;45:153-4.
13. Anglaret X, Saba J, Perronne C, Lacassin F, Longuet P,
Leport C, Vildé JL. Empiric antituberculosis treatment:
benefits for earlier diagnosis and treatment of tuberculosis. Tuberc
Lung Dis 1994;75(5):334–50.
14. Patel SS, Saraiya NV, Tessler HH, Goldstein DA.
Mycobacterial ocular inflammation: delay in diagnosis and other factors
impacting morbidity. JAMA Ophthalmol 2013;131(6):752–8. [PubMed]
15. Kesen MR, Edward DP, Rao NA, Sugar J, Tessler HH,
Goldstein DA. Atypical infectious nodular scleritis. Arch Ophthalmol
2009;127(8):1079-80. [PubMed]
How to cite this article?
Pentapati M, Shah S, Suresh Babu G. Rare case of ocular tuberculous
noduloulcerative scleritis. Int J Med Res Rev 2015;3(5):528-531. doi:
10.17511/ijmrr.2015.i5.096.